We are live on ! Find out more
GILD icon

Gilead Sciences

1,263 hedge funds and large institutions have $116B invested in Gilead Sciences in 2014 Q2 according to their latest regulatory filings, with 163 funds opening new positions, 527 increasing their positions, 461 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 163 | Existing positions closed: 83

46% more funds holding in top 10

Funds holding in top 10: 112164 (+52)

14% more repeat investments, than reductions

Existing positions increased: 527 | Existing positions reduced: 461

6% more funds holding

Funds holding: 1,1891,263 (+74)

0% less capital invested

Capital invested by funds: $116B → $116B (-$569M)

24% less call options, than puts

Call options by funds: $2B | Put options by funds: $2.62B

Holders
1,263
Holders Change
+74
Holders Change %
+6.22%
% of All Funds
36.28%
Holding in Top 10
164
Holding in Top 10 Change
+52
Holding in Top 10 Change %
+46.43%
% of All Funds
4.71%
New
163
Increased
527
Reduced
461
Closed
83
Calls
$2B
Puts
$2.62B
Net Calls
-$624M
Net Calls Change
+$552M
Name Holding Trade Value Shares
Change
Change in
Stake
AT
326
Arvest Trust
Oklahoma
$18.6M +$54.7K +703 +0.3%
LS
327
Livforsakringsbolaget Skandia
Sweden
$18.5M
WC
328
Wexford Capital
Florida
$18.3M +$16M +205,819 +1,372%
GAM
329
Goldentree Asset Management
New York
$18.2M +$12.7M +163,550 +292%
BPB
330
Badgley, Phelps & Bell
Washington
$17.7M +$1.33M +17,081 +9%
ZIM
331
Zacks Investment Management
Illinois
$17.5M +$4.97M +63,870 +43%
Kayne Anderson Rudnick Investment Management
332
Kayne Anderson Rudnick Investment Management
California
$17.3M -$263K -3,382 -2%
ABC
333
Associated Banc-Corp
Wisconsin
$17.3M +$2.24M +28,746 +16%
EIM
334
Essex Investment Management
Massachusetts
$17.2M -$1.53M -19,716 -9%
PTC
335
Philadelphia Trust Company
Pennsylvania
$17.1M +$15.2M +195,645 +1,909%
JCM
336
Jag Capital Management
Missouri
$17.1M +$7.94M +102,021 +98%
BFO
337
Boston Family Office
Massachusetts
$17.1M -$85.5K -1,098 -0.5%
ZDA
338
Zweig-DiMenna Associates
New York
$17M +$3.32M +42,670 +26%
WAM
339
World Asset Management
Michigan
$17M -$81.3K -1,044 -0.5%
NMERB
340
New Mexico Educational Retirement Board
New Mexico
$16.9M +$218K +2,800 +1%
Truist Financial
341
Truist Financial
North Carolina
$16.8M -$585K -7,522 -4%
DBG
342
De Burlo Group
Massachusetts
$16.6M +$1.99M +25,550 +15%
SC
343
Selz Capital
New York
$16.6M +$7.01M +90,000 +82%
NIM
344
Nexus Investment Management
Ontario, Canada
$16.5M +$829K +10,650 +6%
TIP
345
Torray Investment Partners
Maryland
$16.5M +$9.81M +126,045 +174%
BA
346
Boston Advisors
Massachusetts
$16.3M -$1.71M -21,970 -10%
RI
347
Redwood Investments
Massachusetts
$16.2M +$15.3M +195,921 New
FLPIM
348
F.L. Putnam Investment Management
Massachusetts
$16.2M -$557K -7,158 -4%
MOACM
349
Mutual of America Capital Management
New York
$16.1M -$352K -4,525 -2%
FP
350
Foundry Partners
Minnesota
$16M +$1.47M +18,895 +11%

GILD Hedge Fund Activity: Q2 2014 in Review

1,263 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2014, worth a combined $116B — down 0.49% from $116B a quarter earlier.

Buyers outnumbered sellers: 163 funds opened new GILD positions and 83 closed out — a net gain of 80 holders — while 527 added to existing stakes and 461 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $1.16B. The largest seller was BNP Paribas Financial Markets, cutting an estimated $3.85B.

  • 1,263 institutional investors held Gilead Sciences (GILD) as of Q2 2014, up from 1,189 in Q1 2014.
  • Funds reported $116B of Gilead Sciences stock for Q2 2014, down 0.49% quarter-over-quarter.
  • 163 funds opened new Gilead Sciences positions in Q2 2014 and 83 closed out, a net change of +80 holders.
  • The largest Gilead Sciences buyer in Q2 2014 was Capital Research Global Investors, an estimated $1.16B added.
  • The largest Gilead Sciences seller in Q2 2014 was BNP Paribas Financial Markets, an estimated $3.85B sold.

Based on aggregated 13F filings for Q2 2014.